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This study explores the molecular association between 4-(thiophen-2-yl)-1-(4-(4-(trifluoromethyl)phenyl)
piperazin-1-yl)butan-1-one (RTC1), an antidiabetic compound recently reported by our research group with
challenging aqueous solubility, and 2-hydroxypropyl-β-cyclodextrin (HPBCD). The formation of a RTC1/HPBCD
complex resulted in improved solubility. A phase-solubility diagramwas used to determine the complex stability
constant and stoichiometric ratio. 2D 1H NMR spectroscopy was utilized to study the molecular interaction be-
tween RTC1 and HPBCD in the complex. Differential scanning calorimetry and scanning electron microscopy
was also employed to confirm complex formation. In vitro biological evaluation, using a glucose uptake assay,
showed that the homogeneous RTC1/HPBCD complex solution showed the same activity to that of RTC1 alone,
with no reduction in activity due to the presence of HPBCD.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Type 2 diabetes mellitus (T2DM) is now one of the major modern
public health threats in terms of human, social, and economic costs
[1]. T2DM is a chronic condition where blood glucose levels are raised
due to the body's inability to produce sufficient amounts of insulin or
to use insulin effectively. Insulin is produced in the pancreas, is an es-
sential hormone and plays a critical role in the transport of blood glu-
cose into the body's cells. A lack of insulin or a cell's insensitivity to
insulin leads to hyperglycaemia where blood glucose levels are ele-
vated, and which, if left unchecked, can result in organ damage and
the development of disabling and life-threatening health complications
[1,2]. There are a number of T2DM therapeutic options available, some
of which can be administered at early stages of disease development
or as a combination therapy with injectables. These include metformin,
sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) in-
hibitors, sodium-glucose transport protein 2 (SGLT2) inhibitors,
Glucagon-like peptide 1 (GLP-1) receptor agonists and insulin, but the
control of diabetes remains variable and can be unsatisfactory [2–4].
For some sufferers, the therapeutic regimens, side effects, and possible
off-target actions of some options are undesirable and can result in re-
duced compliance [5–8]. As a consequence and taking into account
the projected and rapid growth in the number of those suffering with
diabetes, there is an ever-increasing demand for novel anti-diabetic
therapies with defined mechanisms of action. Recently, we reported
the piperazine containing compounds RTC1 and RTB70, which act
through the inhibition of NADH:ubiquinone oxidoreductase (complex
I of the mitochondrial respiratory chain) to stimulate glucose uptake
and restore the glucose handling abilities of diabetic mice [9]. The re-
duction in NADH:ubiquinone oxidoreductase activity provoked leads
to a change in cellular ADP:ATP and AMP:ATP ratios resulting in the ac-
tivation of AMP-activated protein kinase (AMPK). Once activated, AMPK
rapidly restores cellular energy balance by switching off ATP consuming
anabolic pathways and by switching on ATP generating catabolic path-
ways involving increased glucose uptake [10]. Further studies showed
that RTC1 augmented the signalling capabilities of insulin in C2C12
cells stimulated with tumour necrosis factor-alpha (TNF-α), thus
preventing TNF-α induced insulin resistance through action as an insu-
lin sensitizer [11]. However, throughout these studies RTC1 showed
poor aqueous solubility, which could hamper the subsequent further
development of this promising hit compound.
A number of systems exist which can be employed to improve drug
bioavailability and solubility, ranging from chemical modifications (e.g.
prodrugs, attachment of PEG linkers) to the encapsulation of drugs
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within a suitable vehicle (e.g. liposomes, cyclodextrins). These systems
work by improving certain properties of a drug, such as prematuremet-
abolic degradation or poor water solubility, allowing the drug to reach
its target and evoke a pharmacological response [12]. Cyclodextrins
(CD) can improve the solubility, stability, and bioavailability of drug
molecules through their ability to form a non-covalent inclusion com-
plex [12,13]. Cyclodextrins are chemically formed when glucopyranose
molecules are bound together through α-(1–4) bonds. They are most
commonly composed of 6 (α-CD), 7 (β-CD) or 8 (γ-CD) glucose units
[12]. β-CD appears an attractive choice for many pharmaceutical appli-
cations due to its ready availability and the appropriate size of its cavity,
allowing for the inclusion of thewidest range of drugs [13]. However, its
low aqueous solubility and associated nephrotoxicity limits its use [13].
For this reason, modified CDs have been produced. Hydroxylpropyl-β-
cyclodextrin (HPBCD) is one such modified CD that is employed for
the encapsulation of drugmolecules [14]. It has been used in parenteral,
oral, transdermal, and ocular drug delivery systems due to its high
water solubility and lack of toxicity in vivo [14–16].
The hydrophobic cavity and the hydrophilic exterior of CDs
enable these cyclic oligosaccharides to function as efficient drug de-
livery systems [12,17]. The driving force behind the formation of an
inclusion complex is the release of water molecules from the CD cav-
ity, with electrostatic and hydrophobic interactions, van der Waals
forces, and hydrogen-bonding all contributing to the inclusion of a
drugmolecule [18]. The release of a drugmolecule occurs as these in-
teractions are relatively weak, which allows the free drug and
uncomplexed cyclodextrin to be in equilibrium with the inclusion
complex when in solution [18].
The aim of this work was to establish an aqueous CD based solvent
system for the dissolution of RTC1 and to study the molecular associa-
tion that takes place between RTC1 and HPBCD. A phase-solubility dia-
gram and two dimensional proton nuclear magnetic resonance (2D 1H
NMR) spectroscopywas performed in order to ascertain inclusion com-
plex formation and to estimate the inclusion mode. Differential scan-
ning calorimetry (DSC) and scanning electron microscopy (SEM) were
also employed to allow characterization of the complex in the solid
state. Finally, the in vitro ability of the RTC1/HPBCD complex to stimu-
late glucose uptake in mouse C2C12 cells was determined and com-
pared to RTC1 alone.
2. Results and discussion
RTC1 can be prepared according to our published literature proce-
dure with some minor modifications (Scheme 1 and Supporting infor-
mation) [9]. A two-step process was employed that utilized SNAr and
coupling reactions (Scheme 1). The aryl piperazine 2 was generated
from 4-chlorobenzotrifluoride 1 and piperazine by heating the reaction
to 200 °C under microwave conditions (50% yield). Coupling of the re-
sultant 2 with the commercially available 4-(2-thienyl)butyric acid 3
gave the desired RTC1 in 80% yield (Scheme 1).
A solubility study was conducted in order to prepare an aqueous
0.02 M solution of RTC1 using HPBCD as a complexing agent. The first
attempt involved the use of 20 equivalents of HPBCD in 100% water.
However, this did not result in the dissolution of RTC1. We then ex-
plored the use of DMSO as a co-solvent, in combination with HPBCD,
where a number of variations were explored (Table 1). DMSOwas cho-
sen due to its low toxicity, but also experimental studies in the forma-
tion of inclusion complexes have suggested that stable inclusion
complexes can be formed in the presence of DMSO [19]. The results of
this study are summarized in Table 1, where the use of up to 50%
DMSO still resulted in insolubility, however the combination of 5%
DMSOwith 20 equivalents of HPBCD produced a homogeneous solution
and was considered optimal. The solubilising effect of HPBCD can be
seen in Fig. 1. We suggest that the resultant homogeneous solution of
RTC1 was due, in part, to the formation of an inclusion complex. To
characterize this inclusion complex, a number of analytical techniques
were employed, namely a phase solubility diagram, NMR spectroscopy,
DSC, and SEM.
TheHiguichi and Connorsmethod for phase-solubility diagramswas
employed to explore the effect of HPBCD on the aqueous solubility of
RTC1 (see Supporting information) [20]. As can be seen in Fig. 2, the sol-
ubility of RTC1 increases linearly with increasing concentrations of
HPBCD, and hence is an AL type solubility curve, which indicates the
presence of a water soluble complex. This is themost common complex
observed for drug:CD interactions [14]. The slope, of value 0.012 in this
case, is less than one and suggests the presence of a complex with a 1:1
stoichiometry [20].
The apparent stability constant (K1:1) was estimated according to
Eq. (1), where So is the intrinsic water solubility of the drug and the
Fig. 1. (a) RTC1 in a 5% DMSO/H2O solution without HPBCD. (b) RTC1 in a 5% DMSO/H2O
solution with 20 equivalents of HPBCD.
Table 1
Solubility study for the generation of a 0.02 M RTC1 solution.
% DMSO HPBCD (eq) Solubility
0 20 Insoluble
50 1 Insoluble
50 2 Insoluble
50 5 Insoluble
50 10 Insoluble
50 12 Soluble
10 12 Insoluble
10 18 Insoluble
10 20 Soluble
5 20 Soluble
2 20 Insolublea
a Was soluble initially but precipitate subsequently appeared.
Scheme 1. Synthesis of RTC1. Reagents and conditions: (a) piperazine, NMP, 30 min,
200 °C, MW, 50% yield; (b) 4-(2-thienyl)butyric acid 3, HOBt, TBTU, NEt3, DMF,
overnight, rt, 80% yield [9].
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slope is the slope of the line generated from the phase-solubility
diagram [14].
K1:1 ¼ SlopeSo 1−Slopeð Þ ð1Þ
Table 2
Chemical shifts for free RTC1 and RTC1/HPBCD complex.
Assignment (RTC1) δa (free RTC1) δa (RTC1/HPBCD complex) Δδ
H2, H4 7.0904 7.0784 0.0120
H6 2.5184 2.5078 0.0106
H8 2.9384 2.9289 0.0095
H10 6.8687 6.8621 0.0066
H11 6.9540 6.9465 0.0075
a δ in ppm.
Fig. 2. Phase solubility diagram for RTC1/HPBCD host-guest system at rt.
Fig. 3. 1H NMR spectra (300MHz) in 5% D2O/CD3OD of (a) RTC1 (red) and the inclusion complex (blue) and (b) amagnified view of the spectrum. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
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The intrinsic water solubility (0.32 μM) was calculated using UV-
spectroscopy (see Supporting information). Using Eq. (1), K1:1 was cal-
culated to be 34,755M−1. The value of K1:1 is a useful index to estimate
the degree of binding strength of the complex. Here, the K1:1 is an ap-
proximate value (R2 = 0.9699) and can be compared to that reported
by Upadhye et al. who described a binding constant of 21,137 M−1,
which indicated a strong bonding interaction between the drug mole-
cule Δ9-tetrahydrocannabinol (THC) and a CD [15]. Upadhye also gave
an example of a drug molecule which formed weak, unstable interac-
tions within a CD molecule. In this case the molecule, Δ9-
tetrahydrocannabinol hemisuccinate (THC-HS), a prodrug derivative
of the previously mentioned THC, was found to have a K1:1 value of
562.48 M−1 [15]. The large stability constant value obtained for RTC1
suggests a favourable interaction between the molecule and HPBCD,
with the equilibrium lying in favour of the inclusion complex. Although
the phase diagram suggested the formation of a RTC1/HPBCD complex
with a 1:1 stoichiometry, 20 equivalents of HPBCD was still required
to form a homogeneous solution. This is to be expected, for as explained
by Rojas-Aguirre et al., a phase solubility diagram can indicate the pres-
ence of a complexwith a 1:1 stoichiometry, where the level of complex-
ation can be low and excess CD is needed to fully dissolve the required
concentration of drug [12]. In addition, the use of excess amounts of CD
can achieve solubilisation of drug molecules by the formation of non-
inclusion complexes [21]. Gabelica et al. reported that CD can form
both inclusion and non-inclusion complexes with certain molecules
and that both complexes can exist simultaneously in aqueous solutions
[22]. These non-inclusion complexes arise due to the formation of ag-
gregates consisting of two or more CD molecules and drug/CD com-
plexes. The water soluble aggregates can then function to further
solubilise lipophilic drugs through the formation of a non-inclusion
complex by creating a hydrophobic environment inwhich to accommo-
date the drug. Alternatively, Loftsson et al. suggested that solubilisation
may also occur through the formation of a micelle like structure [21].
The formation of these non-inclusion complexesmay apply to the prep-
aration of the homogeneous 0.02 M solution of RTC1 in 5% aqueous
DMSO. As was reported by Loftsson, these non-inclusion complexes
occur when a high concentration of drug is present [21]. Therefore,
the preparation of a 0.02 M solution of RTC1 may have required 20 eq
of HPBCD to allow the formation of, not only the 1:1 inclusion complex,
but also the non-inclusion complex formed by the presence of a CD:in-
clusion complex aggregate [21].
1H NMR spectroscopic analysis was used to investigate the binding
mode of RTC1 within HPBCD. The encapsulation of RTC1, either by one
molecule of HPBCD or by the formed aggregates, can be seen by changes
in the 1D 1H NMR spectra of RTC1 for the inclusion complex. Full
characterization of the RTC1/HPBCD complex in D2O was not possible,
as RTC1 could not be solubilised in this solvent. Therefore, a 5% D2O/
CD3OD solution was prepared in which both RTC1 and the complex
were independently soluble. This gave the spectra below where the
characteristic peaks of RTC1 were observed within the CD complex
(Fig. 3(b), blue spectrum).
A shift in the resonance of a number of peaks for RTC1was observed
and the difference in chemical shift is shown in (Table 2). This indicates
that RTC1 is in a different environment when it is present in the CD in-
clusion (or non-inclusion) complexes. These small changes in chemical
shifts are common,with Rojas-Aguirre et al. reporting changes in chem-
ical shifts ranging from 0.001 ppm to 0.012 ppm in their study [12]. The
information on the spatial proximity of RTC1 in the CD complexes was
determined bymeans of two-dimensional rotating frameNOE spectros-
copy (ROESY). The 2D ROESY spectrum was also obtained using a 5%
D2O/CD3OD solution with the contour plot revealing an interaction be-
tween H1, H2, H3, H4, H5 and H12 of RTC1 with the internal protons
Ha and Hb of HPBCD, which were assigned by Rojas-Aguirre et al.
(Fig. 4) [12]. This suggests the presence of RTC1 within the cavity of
HPBCD, supporting the formation of an inclusion complex.
The thermoanalytical technique, DSC, was also used to study the
presence of the inclusion complex. The thermal behaviour of the inclu-
sion complexwas compared to that of RTC1, HPBCD, and a physicalmix-
ture of RTC1 and HPBCD (see Supporting information). The DSC curve,
Fig. 5(a), for RTC1 shows a sharp endothermic peak at 94 °C, which is
characteristic of the melting point of RTC1. Fig. 5(b), the curve for
HPBCD, is in accordance with the literature and shows two broad endo-
therms ranging from 25 to 103 °C, due to the loss of water, and 280 to
340 °C, due to decomposition of the CD [12,14]. The physical mixture
shows the characteristic peaks of both RTC1 and HPBCD, with the
sharp peak at 94 °C due to themelting of RTC1 and the broad endotherm
ranging from 25 to 103 °C showing the loss of water from the HPBCD
cavity (Fig. 5(c)). This indicates the absence of any interaction between
RTC1 and HPBCD [12]. The inclusion complex, Fig. 5(d), has a broad en-
dotherm at 25–103 °C due to the loss of water. Work by Rojas-Aguirre
has suggested that this is the loss of water molecules which are bound
to the\\OH groups on the exterior of the CD and not the loss of water
from the cavity [12]. The sharp, endothermic peak observed at 94 °C,
in the DSC curve of RTC1 and the physical mixture is notably absent
from the DSC curve of the inclusion complex. This again suggests the
presence of a complex, whether it is an inclusion or non-inclusion com-
plex [21].
An investigation using SEM analysis was employed and compared
the shape and surface morphologies of HPBCD, RTC1, the physical mix-
ture, and the RTC1/HPBCD complex. Fig. 6 shows the SEM images for
HPBCD, RTC1, the physical mixture, and the RTC1/HPBCD complex at
500 magnifications. HPBCD and RTC1 show distinct morphologies,
with RTC1 appearing to adopt a cluster like arrangement in the micro-
graph. The SEM image of the physicalmixture (Fig. 6(c)) has amorphol-
ogy comparable to that of both RTC1 and HPBCD. The characteristic
clusters observed in the micrograph of RTC1 and the smooth morphol-
ogy of HPBCDcan be seen. Themorphology of theRTC1/HPBCDcomplex
is clearly different from that of the physical mixture and RTC1. Fig. 6(d),
the RTC1/HPBCD complex, shows a smooth solid, without the cluster
like structures observed in the SEM image of RTC1.
The in vitro biological activity of the RTC1/HPBCD complex was in-
vestigated using a glucose uptake assay. This was to elucidate whether
the complexation of RTC1 with HPBCD would hinder its ability to
evoke a biological response. As the stability constant was large
(K1:1 = 34,755 M−1), it was possible that the concentration of free
drug would be too low to evoke a response. The assay was performed
as previously described, using 10 μM of RTC1 (see Supporting informa-
tion) [9]. The results, shown in Fig. 7, indicate that the binding of RTC1 in
theHPBCD did not affect the compounds ability to stimulate glucose up-
take. Although the stability constant was large, indicating the presence
of significant interactions within the inclusion complex, it is still
Fig. 4. ROESY spectrum showing the crosspeaks between the aromatic signals of the
inclusion complex between RTC1 and HPBCD protons.
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Fig. 6. SEM images (20 kV) of (a) RTC1 (b) HPBCD (c) physical mixture of RTC1 and HPBCD (d) RTC1/HPBCD complex at 500× magnification.
Fig. 5. DSC curves: (a) RTC1 (b) HPBCD (c) physical mixture (d) RTC1/HPBCD complex.
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possible for RTC1 to become disassociated from the CD and reach the
target protein.
3. Conclusion
A convenient method for improving the aqueous solubility of RTC1
was identifiedwith the use of the excipientHPBCD. The enhanced aque-
ous solubility is likely due to the formation of a RTC1/HPBCD inclusion
complex, as supported by the phase solubility profile. The presence of
non-inclusion complexes, in addition to the inclusion complex, could
not be ruled out and could account for the large excess of HPBCDneeded
to solubilise RTC1. The resultant complexes were characterized using
analytical techniques such as SEM and DSC, while NMR spectroscopy
allowed for the interaction to be investigated at amolecular level show-
ing an interaction between RTC1 protons and internal protons of
HPBCD. In vitro biological evaluation indicated that the RTC1/HPBCD
complex showed comparable activity (ability to stimulate glucose up-
take) to RTC1 alone, suggesting that RTC1 can disassociate from the
CD and reach the target protein and hence improve bioavailability.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.rechem.2020.100026.
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